The purpose of this study is to compare the effects of chemotherapy and radiation therapy with or without the use of an immunotherapy drug called atezolizumab, which is used to treat bladder cancer. Participants will receive combined chemotherapy and radiation therapy (which is called “chemoradiotherapy”) either with or without the study drug. The chemoradiotherapy is standard-of-care treatment and will be administered for up to 7 weeks. If participants are assigned to the group receiving atezolizumab, they will take the drug for up to 6 months in addition to the chemoradiotherapy. The addition of atezolizumab to the usual treatment could help patients live longer but may cause side effects. The combination of chemotherapy, radiation therapy and atezolizumab is considered experimental.
What is the full name of this clinical trial?
S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Bladder cancer, Urology
Charles Rosser, David Hoffman, Edwin Posadas, Howard Sandler, Hyung Kim, Jeremy Lorber, Jun Gong, Kevin Scher, Leslie Ballas, Timothy Daskivich, Zachary Zumsteg